Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Change in Account Payables (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Change in Account Payables for 2 consecutive years, with -$850019.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables fell 515.31% to -$850019.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$838328.0, a N/A change, with the full-year FY2025 number at -$917663.0, down 214.08% from a year prior.
  • Change in Account Payables was -$850019.0 for Q4 2025 at Neuphoria Therapeutics, down from $216359.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $580663.0 in Q2 2025 to a low of -$917668.0 in Q3 2024.